This inventor holds 1 USPTO granted patent. Top assignee: Nitto-Denko Corporation. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Natsuko Kagehisa: Innovator in Diabetes Treatment
Introduction
Natsuko Kagehisa, located in Osaka, Japan, is a prominent inventor known for her groundbreaking work in the field of diabetes treatment. With a strong focus on innovative peptide delivery systems, her research has the potential to significantly impact the management of diabetes and related diseases.
Latest Patents
Kagehisa holds a patent for a novel method titled "Transepithelial delivery of peptides with incretin hormone activities." This patent discloses compositions and methods for treating diabetes using peptides with incretin hormone activity, specifically emphasizing GLP-1 and its analogs. The characteristic of her invention lies in the use of transepithelial carrier peptides that enhance the delivery of these vital hormones through the epithelial barrier, thereby improving therapeutic efficacy. The innovative delivery system includes a pressure-sensitive adhesive layer, allowing for convenient administration via plasters or patches.
Career Highlights
Natsuko Kagehisa is associated with Nitto Denko Corporation, where she actively contributes to advancing medical technologies. Her work exemplifies the company’s commitment to providing innovative solutions in healthcare. With her expertise and dedication, she has positioned herself as a leader in biotechnology and pharmaceutical developments.
Collaborations
Throughout her career, Kagehisa has collaborated with notable colleagues such as Chieko Kitaura and Kenjiro Minomi. Together, they combine their skills and knowledge to explore new horizons in diabetes treatment, maximizing the potential for innovative breakthroughs and improved patient outcomes.
Conclusion
Natsuko Kagehisa is a visionary inventor whose work in peptide delivery systems holds promise for diabetes management. Her contributions not only enhance the scientific community’s understanding of incretin hormones but also pave the way for new therapeutic options. As she continues to innovate at Nitto Denko Corporation, the impact of her work is poised to resonate in the healthcare sector for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile